Cited 0 times in
Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김지수 | - |
dc.contributor.author | 김현정 | - |
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 이미수 | - |
dc.contributor.author | 이승환 | - |
dc.contributor.author | 최영득 | - |
dc.date.accessioned | 2024-08-19T00:06:36Z | - |
dc.date.available | 2024-08-19T00:06:36Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 1619-7070 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/200218 | - |
dc.description.abstract | Purpose: [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [18F]FDG PET/CT. This study aimed to evaluate [18F]PSMA-1007 and [18F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively. Method: This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [18F]PSMA-1007 and [18F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed. Results: All 42 index tumours were detected on [18F]PSMA-1007 PET/CT, whereas only 15 were detected on [18F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUVmax for [18F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6-7 vs. GS 8-10; 12.1 vs. 20.1, p < 0.05). Tumours with [18F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [18F]PSMA-1007 uptake than tumours without [18F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [18F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [18F]FDG negative tumours but in 53.3% (8/15) of patients with [18F]FDG positive tumours (p = 0.013). Conclusions: [18F]PSMA-1007 PET/CT was superior to [18F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [18F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer-Verlag Berlin | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Fluorodeoxyglucose F18* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging* | - |
dc.subject.MESH | Niacinamide / analogs & derivatives* | - |
dc.subject.MESH | Oligopeptides / chemistry | - |
dc.subject.MESH | Positron Emission Tomography Computed Tomography* | - |
dc.subject.MESH | Postoperative Period | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Prostatic Neoplasms* / diagnostic imaging | - |
dc.subject.MESH | Prostatic Neoplasms* / pathology | - |
dc.subject.MESH | Prostatic Neoplasms* / surgery | - |
dc.subject.MESH | Radiopharmaceuticals | - |
dc.title | Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | BioMedical Science Institute (의생명과학부) | - |
dc.contributor.googleauthor | Jisu Kim | - |
dc.contributor.googleauthor | Seunghwan Lee | - |
dc.contributor.googleauthor | Dongwoo Kim | - |
dc.contributor.googleauthor | Hyun Jeong Kim | - |
dc.contributor.googleauthor | Kyeong Taek Oh | - |
dc.contributor.googleauthor | Sun Jung Kim | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Frederik L Giesel | - |
dc.contributor.googleauthor | Klaus Kopka | - |
dc.contributor.googleauthor | Alexander Hoepping | - |
dc.contributor.googleauthor | Misu Lee | - |
dc.contributor.googleauthor | Mijin Yun | - |
dc.identifier.doi | 10.1007/s00259-023-06585-7 | - |
dc.contributor.localId | A00969 | - |
dc.contributor.localId | A01129 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A05374 | - |
dc.contributor.localId | A02938 | - |
dc.contributor.localId | A04111 | - |
dc.relation.journalcode | J00833 | - |
dc.identifier.eissn | 1619-7089 | - |
dc.identifier.pmid | 38200396 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00259-023-06585-7 | - |
dc.subject.keyword | Biochemical failure | - |
dc.subject.keyword | Cancer metabolism | - |
dc.subject.keyword | Cancer staging | - |
dc.subject.keyword | Prostate | - |
dc.subject.keyword | [18F]FDG | - |
dc.subject.keyword | [18F]PSMA-1007 PET/CT | - |
dc.contributor.alternativeName | Kim, Ji Su | - |
dc.contributor.affiliatedAuthor | 김지수 | - |
dc.contributor.affiliatedAuthor | 김현정 | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 이미수 | - |
dc.contributor.affiliatedAuthor | 이승환 | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.citation.volume | 51 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1763 | - |
dc.citation.endPage | 1772 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.51(6) : 1763-1772, 2024-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.